There is no hazardous surcharge associated with this product.
There is no packaging charge associated with this product.
For Research Purposes only. Not for Personal use.
All compounds supplied are strictly intended for laboratory, research, analytical, and scientific use only. They are not meant for human consumption, therapeutic use, or any form of clinical application.
"Hale, J.J., et al.: J. Med. Chem., 41, 4607 (1998), Campos, D., et al.: J. Clin. Oncol., 19, 1759 (2001), Van Belle, S., et al.: Cancer, 94, 3032 (2002); Majumdar, A.K., et al.: J. Clin. Pharmacol., 46, 291 (2006)"
"4-Defluoro-4-(p-fluorophenyl)aprepitant-13C, 15N2 is the labeled analogue of 4-Defluoro-4-(p-fluorophenyl)aprepitant (D228722), an impurity of Aprepitant (A729800), a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Antiemetic."
Hazard Compound
Refer MSDS for complete information.
Overview
"4-Defluoro-4-(p-fluorophenyl)aprepitant-13C, 15N2 is the labeled analogue of 4-Defluoro-4-(p-fluorophenyl)aprepitant (D228722), an impurity of Aprepitant (A729800), a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E1. Antiemetic."
